Soleno Therapeutics, Inc. announced the passing of William G. Harris, who served as a valued member of Soleno?s Board of Directors since June 2014 and Chairman of the Audit Committee. Mr. Harris? career in the biopharmaceutical industry began in the early 1990s with several positions at Gilead Sciences, ultimately becoming Director of Finance.
He later held several roles of increasing responsibility at Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was Senior Vice President and Chief Financial Officer. Coulter was acquired by Corixa Corp., a developer of immunotherapeutic products, in 2000. He went on to become Senior Vice President of Finance and Chief Financial Officer of Xenoport, Inc., which was acquired by Arbor Pharmaceuticals, LLC, a specialty pharmaceutical company, in 2016.
Soleno expects that long-serving Board and Audit Committee member Andrew Sinclair will take over the position of Chair of the Audit Committee. Dr. Sinclair qualifies as an ?audit committee financial expert? pursuant to the definition adopted by the Securities and Exchange Commission and the listing rules of the Nasdaq Stock Market.
